Prognosis

AstraZeneca to Test Combining Its Covid-19 Vaccine With Russia’s

  • Company to test combination of AZD1222 and Sputnik V shot
  • Combination may lead to stronger immune response, company says
A vial of the Sputnik V Covid-19 vaccine, developed by the Gamaleya Institute.Photographer: Andrey Rudakov/Bloomberg
Lock
This article is for subscribers only.

AstraZeneca Plc plans to start a clinical trial combining its Covid-19 vaccine with Russia’s Sputnik V in an effort to determine whether the two inoculations work better together than individually.

This “may be an important step in generating wider protection through a stronger immune response and better accessibility,” the company said in a website statement. Volunteers aged 18 and older will be enrolled in the trial that will assess safety and immunogenicity of a combination of AZD1222, developed by AstraZeneca and Oxford University and Sputnik V, developed by Russia’s Gamaleya Institute, according to the statement.